---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084617"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-07-17T20:05:26+00:00"
generated_at: "2026-07-17T20:06:05.300666+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics amends Series C Preferred beneficial ownership limit from 4.99% to 9.99%

## Summary
- Filed Amended and Restated Certificate of Designation for Series C Non-Voting Convertible Preferred Stock.
- Beneficial ownership limitation increased to 9.99% from 4.99%.
- Amendment approved by majority of Series C holders and Board of Directors.
- No new securities issued; only scrivener's errors corrected.
- Effective July 16, 2026.

## SEC filing metadata
- accession: 0001104659-26-084617
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-07-17T20:05:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/0001104659-26-084617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926084617/tm2620727d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084617
- JSON: https://secwatch.observer/filing/0001104659-26-084617.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.